Clear. 40   F New York
AI-Powered News Summarizer
Top Stories

Pfizer and BioNTech begin advanced coronavirus vaccine trial

July 28, 2020. Summarized by summa-bot.

Drug giant Pfizer and its partner BioNTech have begun an advanced trial of one of their experimental coronavirus vaccines in volunteers in the United States.

(CNN)Drug giant Pfizer and its partner BioNTech have begun an advanced trial of one of their experimental coronavirus vaccines in volunteers in the United States.

The combined Phase 2/3 trial, which looks for safety, efficacy and optimal dosing of a vaccine or drug, will include up to 30,000 participants.

It was the second advanced trial of a coronavirus vaccine to get under way in the United States Monday.

Earlier Monday, Moderna started a Phase 3 trial in the United States of its experimental vaccine.

Pfizer's vaccine is different, but also uses an experimental approach that employs genetic material to stimulate an immune response against a key part of the coronavirus.

Earlier this month, Pfizer and BioNTech released preliminary data showing that one of their vaccines, known only by its experimental name BNT162b1, appeared safe and elicited antibody and T-cell immune responses in a Phase 1/2 trial.

Pfizer's coronavirus vaccines all use pieces of genetic material to prompt the vaccine recipient to make antibodies against specific parts of the coronavirus.

Pfizer and BioNTech's first vaccine targeted a piece of the spike protein, a structure the virus uses to infect human cells.

The second vaccine, being moved into advanced trials, targets the entire spike structure.

Both versions of Pfizer's vaccine elicit antibody responses as well as immune cells called T-cells, the company said.

A Phase 1 study typically involves a small number of people and focuses on whether a vaccine is safe and elicits some kind of immune response.

In Phase 2, the clinical study is expanded and the vaccine is given to people who have characteristics -- such as age and physical health -- similar to those for whom the new vaccine is intended, according to the US Centers for Disease Control and Prevention.

If the vaccine works, Pfizer and BioNTech say they're on track to seek regulatory review as early as October, and if it wins emergency authorization from the US Food and Drug Administration, they could supply up to 100 million doses by the end of 2020, and about 1. 3 billion by the end of 2021.

Last week the US Department of Health and Human Services and Department of Defense announced a $1. 95 billion agreement with Pfizer to produce 100 million doses of a Covid-19 vaccine.

Pfizer and BioNTech's vaccine is one of 25 in clinical trials around the world, according to the World Health Organization.

Summarizer is on Google News. Now you can get the latest AI summarized news on your favorite news platform.

Don't like Google News? We have an RSS Feed for you.

Suggestions